Business Context and Reporting Period
NanoViricides, Inc. (NNVC), a Delaware corporation, filed this Form 8-K on May 20, 2026, reporting events occurring on May 15 and May 18, 2026. The company is incorporated in Delaware and its principal executive offices are located in Shelton, Connecticut.
Key Financial Metrics and Transaction Details
The filing details a registered direct offering that closed on May 18, 2026. Key financial terms include:
- Gross Proceeds: Approximately $2.0 million.
- Common Stock Issued: 1,133,334 shares at $1.50 per share.
- Pre-Funded Warrants: Up to 200,000 warrants at $1.49999 per warrant (exercisable at $0.00001).
- Common Warrants: 1,333,334 warrants exercisable at $1.75 per share, exercisable after six months, expiring in three years.
- Placement Agent Fee: 7.0% of aggregate gross proceeds plus up to $50,000 in reimbursable expenses.
The filing does not provide specific figures for revenue, profit, cash flow, margins, or existing debt levels. The company intends to use net proceeds for working capital, capital expenditures, research and development, clinical trials, and strategic acquisitions.
Material Changes and Agreements
The primary material change is the entry into a Securities Purchase Agreement and the subsequent closing of the equity offering. Additional material agreements include:
- Placement Agency Agreement: D. Boral Capital LLC served as the exclusive placement agent.
- Lock-Up Agreement: The CEO agreed to a 30-day lock-up period following the closing date, prohibiting the sale or transfer of shares.
- Issuance Restrictions: The company agreed not to issue additional common stock or equivalents for 30 days post-closing (with specific exceptions for a $50 million shelf registration and employee plans) and suspended At-The-Market offerings for 10 days.
Outlook, Risks, and Management Commentary
Management indicated the proceeds will support operational needs including clinical trial expenditures and potential acquisitions. The company committed to filing a resale registration statement within 30 days of closing to facilitate the sale of shares underlying the warrants. No specific forward-looking guidance regarding revenue or earnings was provided in this filing. The filing notes that the description of the warrants and agreements is qualified by reference to the full text of the exhibits.
Investor Verification Checklist
- Verify the final net proceeds after deducting the 7% placement fee and offering expenses.
- Confirm the effective date of the Resale Registration Statement for the warrant shares.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for any additional covenants or conditions.
- Monitor the company's cash burn rate relative to the $2.0 million raised to assess runway for clinical trials.
- Check for any subsequent filings regarding the $50 million shelf registration mentioned in the issuance restrictions.